# Trinity Biotech Plc (TRIB)

Source page: https://stoqly.net/companies/trib

- **Ticker:** TRIB (Nasdaq)
- **Sector:** Health Care / In Vitro & In Vivo Diagnostic Substances
- **SEC CIK:** 0000888721
- **Latest annual report:** 20-F filed 2026-04-30 (https://www.sec.gov/Archives/edgar/data/888721/000155485526000848/trib-20251231.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $6.26 on 2026-10-30
- **Revenue (FY2025):** $43.8M
- **Revenue growth:** −28.9%
- **Revenue growth, 5-year CAGR:** −15.6%
- **Gross margin:** 38.6%
- **Operating margin:** −36.1%
- **Net margin:** −85.4%
- **Free cash flow:** −$6.0M
- **Free cash flow margin:** −13.7%
- **Net debt:** −$4.9M
- **Change in share count:** +3.4%
- **Piotroski F-score:** 3/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/trib/figures.csv

| US$ millions | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 100 | 99 | 97 | 90 | 102 | 81 | 63 | 57 | 62 | 44 |
| Operating income | -40 | -38 | -20 | -24 | 0 | 4 | -19 | -27 | -21 | -16 |
| Net income | -101 | -40 | -22 | -29 | -6 | 1 | -41 | -24 | -32 | -37 |
| Operating cash flow | 10 | 9 | 7 | 5 | 24 | 13 | -1 | -12 | -4 | -6 |
| Free cash flow | 6 | 4 | 0 | 3 | 21 | 11 | -2 | -12 | -5 | -6 |
| Cash | 77 | 58 | 30 | 15 | 27 | 26 | 7 | 4 | 5 | 5 |
| Debt and leases | 1 | 1 | 100 | 1 | 1 | 167 | 0 | 0 | 0 | 0 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.